Cochlear Limited (ASX: COH) for Contrarians
Despite solid results in FY 2023 and a robust forecast for FY 2024, the analyst community’s view of Cochlear is mixed, with a consensus HOLD recommendation.
Stay updated with breaking news from Baker Young. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Despite solid results in FY 2023 and a robust forecast for FY 2024, the analyst community’s view of Cochlear is mixed, with a consensus HOLD recommendation.
Take a look at the buy, hold and sell recommendations for the week of 18th December 2023 from 3 top experts.
Shares in listed South Australian-based companies were largely positive last week amid optimism that interest rates have peaked.
In the space of just five days, shares in biotech LBT Innovations jumped up by 220 per cent.
Clean Seas was one of the week’s biggest Losers but completed a $9.5 million raise and announced an operational review of the business on Friday.